Literature DB >> 19124371

Adverse events associated with intranasal influenza vaccine in the United States.

Neetu Vasu1, Gisoo Ghaffari, Ethan T Craig, Timothy J Craig.   

Abstract

METHODS: The goal of this review was to analyze the post-vaccination adverse effects associated with Live Attenuated Influenza Vaccine (LAIV) compared to those of the Injectable Trivalent Inactivated Vaccine (TIV) in patients with egg allergy and asthma. PubMed, Ovid, and Google searches were conducted. Searched articles relating to allergic reactions, asthma or food allergy, and LAIV were reviewed.
RESULTS: Similar or superior efficacy of LAIV compared to TIV was reported by various studies. Respiratory symptoms were the most common adverse events following both vaccinations. Although no evidence was found of a direct causal relationship between intranasal influenza vaccine and anaphylaxis due to egg allergy, a number of cases of anaphylaxis were reported. To date, there are no studies directly comparing the frequency of anaphylactic reactions between the two vaccines.
CONCLUSIONS: The safety of LAIV in individuals with unstable asthma and egg allergy has not been established and it should be avoided in these populations. For patients with unstable asthma, TIV should remain the therapy of choice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19124371     DOI: 10.1177/1753465808093933

Source DB:  PubMed          Journal:  Ther Adv Respir Dis        ISSN: 1753-4658            Impact factor:   4.031


  6 in total

1.  Recommendations on the use of live, attenuated influenza vaccine (FluMist®): Supplemental Statement on Seasonal Influenza Vaccine for 2011-2012 An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI).

Authors: 
Journal:  Can Commun Dis Rep       Date:  2011-11-30

Review 2.  Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?

Authors:  Mattia Tiboni; Luca Casettari; Lisbeth Illum
Journal:  Int J Pharm       Date:  2021-05-06       Impact factor: 6.510

3.  International Consensus (ICON): allergic reactions to vaccines.

Authors:  Stephen C Dreskin; Neal A Halsey; John M Kelso; Robert A Wood; Donna S Hummell; Kathryn M Edwards; Jean-Christoph Caubet; Renata J M Engler; Michael S Gold; Claude Ponvert; Pascal Demoly; Mario Sanchez-Borges; Antonella Muraro; James T Li; Menachem Rottem; Lanny J Rosenwasser
Journal:  World Allergy Organ J       Date:  2016-09-16       Impact factor: 4.084

4.  Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.

Authors:  Justin Chin; YaQun Zhou; Chijen L Chen; Christine M Lomiguen; Suzanne McClelland; Mary Lee-Wong
Journal:  Cureus       Date:  2021-01-07

Review 5.  COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.

Authors:  Kuldeep Dhama; Manish Dhawan; Ruchi Tiwari; Talha Bin Emran; Saikat Mitra; Ali A Rabaan; Saad Alhumaid; Zainab Al Alawi; Abbas Al Mutair
Journal:  Hum Vaccin Immunother       Date:  2022-03-08       Impact factor: 4.526

6.  Non-adjuvanted interferon-armed RBD protein nasal drops protect airway infection from SARS-CoV-2.

Authors:  Yifan Lin; Jing Sun; Xuezhi Cao; Xiuye Wang; Xi Chen; Hairong Xu; Jincun Zhao; Yang-Xin Fu; Hua Peng
Journal:  Cell Discov       Date:  2022-05-10       Impact factor: 38.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.